Skip to main content

Treat severe cases of infection at COV with XAV-19

Project description

Polyclonal antibodies for the treatment of COVID-19 infection

Polyclonal antibodies are very efficient and superior to monoclonal antibodies as a treatment option for bacterial or viral infectious diseases. French company XENOTHERA has developed a platform for the production of glyco-humanised polyclonal antibodies with high efficiency and optimised safety. Currently, XENOTHERA is working on the development of a new treatment against COVID-19 based on this technology. The product, XAV-19, is expected to treat patients suffering from moderate to severe pneumonia. The purpose of the EU-funded BRIGHT project is to prepare the product and complete all necessary actions for a phase 2 double-blind clinical trial to demonstrate its efficacy.

Field of science

  • /medical and health sciences/health sciences/infectious disease/RNA virus/coronavirus

Call for proposal

H2020-EIC-SMEInst-2018-2020-3
See other projects for this call

Funding Scheme

SME-2b - SME Instrument (grant only and blended finance)

Coordinator

XENOTHERA
Address
1 Rue Vauban
44000 Nantes
France
Activity type
Private for-profit entities (excluding Higher or Secondary Education Establishments)
EU contribution
€ 2 162 650